Metabolomics in Drug Metabolism, Drug-Drug Interactions, and Drug Toxicity
A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Pharmacology and Drug Metabolism".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 465
Special Issue Editor
Special Issue Information
Dear Colleagues,
Issues related to drug safety remain a major bottleneck in drug discovery and development. Recent technological advancements in metabolomics have enabled researchers to measure a large number of compounds in large sets of samples, as well as in single cells. These new advancements have helped us to gain insights into the mechanisms of drug toxicity, translatability to humans, prediction of safety events, mitigation of side effects, and development of safety biomarkers. Metabolomics applied to drug metabolism, drug–endobiotic interactions, and drug–drug (food) interactions offers an ideal opportunity to study the toxicological effects of drugs.
This Special Issue is devoted to metabolomics in drug metabolism, drug–drug (food) interactions, and drug toxicity. The topics that will be covered include studies on the metabolomic analyses of the fate of drugs and host responses to drugs (including new modalities such as peptides, antibody–drug conjugates, protein therapeutics, and oligonucleotide therapeutics), as well as endogenous probes for drug–drug (food) interactions. Additional topics include metabolomic analyses of studying the mechanism, prediction, and safety biomarkers of drug toxicity. Other topics with a similar focus will also be considered.
Dr. Pengcheng Wang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metabolomics
- drug/xenobiotic metabolism
- drug–drug interactions
- drug toxicity
- ADME
- new modalities peptides
- antibody-drug conjugates
- protein therapeutics
- oligonucleotide therapeutics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
